Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSPI on FDA advisory committees

This article was originally published in The Tan Sheet

Executive Summary

FDA should "immediately reform the process of choosing members of advisory committees" and end the "promiscuous use of scientists with conflicts of interest," the Center for Science in the Public Interest says in a FDL-1March 10 letter to Acting Commissioner Lester Crawford, PhD. The letter closely follows a CSPI investigation finding that 10 of the 32 advisory committee members during the February meeting on COX-2 inhibitors had financial ties to Pfizer, Merck and Novartis (1"The Tan Sheet" March 7, 2005, p. 15). FDA also should "limit the number of panel members with any industry ties to no more than half the committee," the letter asserts. A list of proposed advisory panelists and their biographies should be posted no later than 30 days before the meeting and "not within the last 72 hours as is presently the case." The public should then be given 20 days in which to comment on the proposed roster, CSPI says...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS097973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel